Skip to content
Adjuvance Technologies

Adjuvance Technologies

Empowering health.

  • About Us
  • Our Technology
  • Our Leadership
    • Management Team
    • Board of Directors
  • Investors & Media
  • Contact

Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer

By jgardnerMay 20, 2013Publications
Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer

Adjuvance’s co-founding scientists review the application of natural and synthetic QS-21 in cancer vaccinology.

Ragupathi_nihms202306

Post navigation

KEY PATENT AWARDED TO ADJUVANCE CO-FOUNDERS FOR PIONEERING METHOD OF PRODUCING RARE VACCINE COMPONENT.
Nature Chemistry: Development of a minimal saponin vaccine adjuvant based on QS-21

Recent Posts

  • ADJUVANCE TECHNOLOGIES ANNOUNCES NIH FUNDING FOR COVID-19 VACCINE RESEARCH
  • ADJUVANCE TECHNOLOGIES ANNOUNCES $20 MILLION SERIES A INVESTMENT FROM MORNINGSIDE VENTURE INVESTMENTS
  • Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine
  • NEJM Reports Efficacy of QS-21 Containing Herpes Zoster Subunit Vaccine
  • Vaccine Adjuvant Systems containing monophosphoryl lipid A andQS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination
Copyright © All rights reserved. Theme Businessbiz by Sensational Theme